

# Bruce R Blazar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6993192/publications.pdf>

Version: 2024-02-01

527  
papers

48,200  
citations

1070

116  
h-index

2750

198  
g-index

562  
all docs

562  
docs citations

562  
times ranked

42852  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. <i>Journal of Experimental Medicine</i> , 2010, 207, 2187-2194.	4.2	1,652
2	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. <i>Blood</i> , 2005, 105, 3051-3057.	0.6	1,574
3	The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. <i>Blood</i> , 2002, 99, 3493-3499.	0.6	978
4	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. <i>Blood</i> , 2011, 117, 1061-1070.	0.6	926
5	Acute Graft-versus-Host Disease – Biologic Process, Prevention, and Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 2167-2179.	13.9	822
6	Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers. <i>New England Journal of Medicine</i> , 2004, 351, 2590-2598.	13.9	791
7	Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. <i>Science</i> , 2017, 355, 1423-1427.	6.0	753
8	Advances in graft-versus-host disease biology and therapy. <i>Nature Reviews Immunology</i> , 2012, 12, 443-458.	10.6	746
9	IL-2 Receptor $\beta$ -Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells. <i>Journal of Immunology</i> , 2007, 178, 280-290.	0.4	709
10	Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. <i>Journal of Clinical Investigation</i> , 2007, 117, 2570-2582.	3.9	698
11	Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. <i>Journal of Experimental Medicine</i> , 2012, 209, 903-911.	4.2	552
12	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 141-151.	15.2	539
13	Cd4+CD25+ Immune Regulatory Cells Are Required for Induction of Tolerance to Alloantigen via Costimulatory Blockade. <i>Journal of Experimental Medicine</i> , 2001, 193, 1311-1318.	4.2	536
14	Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host Disease. <i>Immunity</i> , 2012, 37, 339-350.	6.6	509
15	Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. <i>Blood</i> , 2007, 110, 3064-3070.	0.6	489
16	Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. <i>New England Journal of Medicine</i> , 2017, 377, 2565-2579.	13.9	469
17	Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Annual Review of Immunology</i> , 2007, 25, 139-170.	9.5	454
18	Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. <i>Cell</i> , 2018, 175, 1780-1795.e19.	13.5	445

#	ARTICLE	IF	CITATIONS
19	Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. <i>Science Translational Medicine</i> , 2013, 5, 179ra43.	5.8	401
20	Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning. <i>Immunity</i> , 2009, 30, 656-665.	6.6	400
21	Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2001, 97, 1458-1466.	0.6	396
22	The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation. <i>Journal of Immunology</i> , 2008, 181, 5396-5404.	0.4	394
23	Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. <i>Blood</i> , 2010, 116, 5738-5747.	0.6	384
24	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. <i>Blood</i> , 2014, 123, 3855-3863.	0.6	357
25	Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. <i>Blood</i> , 2002, 100, 3825-3827.	0.6	356
26	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017, 130, 2243-2250.	0.6	352
27	Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells. <i>Stem Cells</i> , 2010, 28, 1446-1455.	1.4	348
28	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. <i>Blood</i> , 2016, 127, 1044-1051.	0.6	333
29	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234.	2.0	328
30	Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa. <i>New England Journal of Medicine</i> , 2010, 363, 629-639.	13.9	326
31	Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T <sub>regs</sub> ) with Minimal Loss of in Vivo Functional Activity. <i>Science Translational Medicine</i> , 2011, 3, 83ra41.	5.8	326
32	L-Selectinhi but not the L-selectinlo CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. <i>Blood</i> , 2004, 104, 3804-3812.	0.6	324
33	Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. <i>Blood</i> , 2012, 119, 3064-3072.	0.6	318
34	Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN- $\gamma$ -Dependent Mechanism. <i>Journal of Immunology</i> , 2003, 171, 1272-1277.	0.4	305
35	IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, <i>In Vivo</i> Expansion, and Enhanced Function. <i>Clinical Cancer Research</i> , 2016, 22, 3440-3450.	3.2	291
36	Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft. <i>Cell Stem Cell</i> , 2016, 18, 144-155.	5.2	289

#	ARTICLE	IF	CITATIONS
37	Leukocyte migration and graft-versus-host disease. <i>Blood</i> , 2005, 105, 4191-4199.	0.6	287
38	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 3865-3874.	0.6	285
39	Vstm3 is a member of the CD28 family and an important modulator of T cell function. <i>European Journal of Immunology</i> , 2011, 41, 902-915.	1.6	285
40	Cord blood CD4+CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. <i>Blood</i> , 2005, 105, 750-758.	0.6	276
41	In vitro differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. <i>Blood</i> , 2009, 113, 1365-1374.	0.6	272
42	Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. <i>Blood</i> , 2002, 99, 4592-4600.	0.6	265
43	Protein Kinase C- $\delta$ Mediates Negative Feedback on Regulatory T Cell Function. <i>Science</i> , 2010, 328, 372-376.	6.0	261
44	Acute graft-versus-host disease: from the bench to the bedside. <i>Blood</i> , 2009, 114, 4327-4336.	0.6	257
45	Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. <i>Nature</i> , 2019, 572, 254-259.	13.7	246
46	Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8120-8125.	3.3	238
47	TALEN-based Gene Correction for Epidermolysis Bullosa. <i>Molecular Therapy</i> , 2013, 21, 1151-1159.	3.7	232
48	The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. <i>Blood</i> , 2003, 102, 303-310.	0.6	229
49	Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. <i>Blood</i> , 2005, 106, 3300-3307.	0.6	227
50	Polyamines and eIF5A Hypusination Modulate Mitochondrial Respiration and Macrophage Activation. <i>Cell Metabolism</i> , 2019, 30, 352-363.e8.	7.2	223
51	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. <i>Blood</i> , 2012, 119, 1570-1580.	0.6	221
52	CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. <i>Blood</i> , 2014, 123, 3016-3026.	0.6	220
53	p27kip1 functions as an energy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. <i>Nature Medicine</i> , 2000, 6, 290-297.	15.2	216
54	Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. <i>Blood</i> , 2017, 129, 13-21.	0.6	216

#	ARTICLE	IF	CITATIONS
55	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
56	Mitochondrial Integrity Regulated by Lipid Metabolism Is a Cell-Intrinsic Checkpoint for Treg Suppressive Function. <i>Cell Metabolism</i> , 2020, 31, 422-437.e5.	7.2	215
57	PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	0.6	214
58	The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8+ T cells. <i>Nature</i> , 2018, 559, 264-268.	13.7	209
59	Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. <i>Blood</i> , 2007, 109, 2529-2537.	0.6	208
60	Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. <i>Blood</i> , 2005, 105, 2227-2234.	0.6	201
61	Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. <i>Blood</i> , 2002, 100, 682-691.	0.6	197
62	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
63	Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. <i>Nature Communications</i> , 2019, 10, 567.	5.8	193
64	Generation and Large-Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft-Versus-Host Disease. <i>American Journal of Transplantation</i> , 2011, 11, 1148-1157.	2.6	192
65	Long-term outcome of Hurler syndrome following bone marrow transplantation. <i>American Journal of Medical Genetics Part A</i> , 1993, 46, 209-218.	2.4	190
66	Engineering lymphocyte subsets: tools, trials and tribulations. <i>Nature Reviews Immunology</i> , 2009, 9, 704-716.	10.6	185
67	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16814-16819.	3.3	185
68	IL-33 Is an Unconventional Alarmin That Stimulates IL-2 Secretion by Dendritic Cells To Selectively Expand IL-33R/ST2+ Regulatory T Cells. <i>Journal of Immunology</i> , 2014, 193, 4010-4020.	0.4	185
69	Thymic T-cell development in allogeneic stem cell transplantation. <i>Blood</i> , 2011, 117, 6768-6776.	0.6	184
70	Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. <i>Cancer Discovery</i> , 2018, 8, 750-763.	7.7	184
71	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	0.6	179
72	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 130-137.	0.6	176

#	ARTICLE	IF	CITATIONS
73	Follicular regulatory T cells control humoral and allergic immunity by restraining early B cell responses. <i>Nature Immunology</i> , 2019, 20, 1360-1371.	7.0	176
74	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	3.9	173
75	CSF-1 $\alpha$ -dependent donor-derived macrophages mediate chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4266-4280.	3.9	173
76	Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. <i>Molecular Therapy</i> , 2016, 24, 570-581.	3.7	168
77	Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. <i>Blood</i> , 2002, 100, 3479-3482.	0.6	167
78	The PTEN pathway in T $\text{reg}$ is a critical driver of the suppressive tumor microenvironment. <i>Science Advances</i> , 2015, 1, e1500845.	4.7	167
79	Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	166
80	MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. <i>Immunity</i> , 2019, 51, 885-898.e7.	6.6	164
81	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1970-1980.	2.5	164
82	Donor CD4 <sup>+</sup> Foxp3 <sup>+</sup> regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. <i>Blood</i> , 2014, 124, 2131-2141.	0.6	162
83	IL-10 and TGF- $\beta$ induce alloreactive CD4 <sup>+</sup> CD25 <sup>+</sup> T cells to acquire regulatory cell function. <i>Blood</i> , 2003, 101, 5076-5083.	0.6	161
84	The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo. <i>Journal of Immunology</i> , 2011, 187, 1097-1105.	0.4	159
85	An Inherently Bifunctional Subset of Foxp3 <sup>+</sup> T Helper Cells Is Controlled by the Transcription Factor Eos. <i>Immunity</i> , 2013, 38, 998-1012.	6.6	159
86	Reprogrammed Foxp3 <sup>+</sup> Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8 <sup>+</sup> T Cell Priming in Naive Mice. <i>Immunity</i> , 2010, 33, 942-954.	6.6	157
87	Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. <i>Blood</i> , 2013, 122, 3062-3073.	0.6	156
88	VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance. <i>Science</i> , 2020, 367, .	6.0	156
89	PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	151
90	Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). <i>Blood</i> , 2006, 108, 3216-3222.	0.6	147

#	ARTICLE	IF	CITATIONS
91	CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR $\alpha$ repertoire. <i>Blood</i> , 2015, 125, 3835-3850.	0.6	147
92	Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2016, 76, 5696-5706.	0.4	146
93	Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. <i>Blood</i> , 2008, 111, 3257-3265.	0.6	145
94	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016, 127, 2144-2154.	0.6	145
95	Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. <i>Blood</i> , 2011, 117, 3268-3276.	0.6	143
96	Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. <i>Blood</i> , 2009, 114, 3793-3802.	0.6	140
97	Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. <i>Blood</i> , 2001, 97, 3132-3137.	0.6	139
98	Induced Pluripotent Stem Cells from Individuals with Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2011, 131, 848-856.	0.3	139
99	Ligation of 4-1BB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients. <i>Journal of Immunology</i> , 2001, 166, 3174-3183.	0.4	135
100	Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3202-3208.	0.8	135
101	Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 40-46.	2.0	134
102	Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. <i>Blood</i> , 2008, 112, 2847-2857.	0.6	134
103	The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. <i>Blood</i> , 2015, 125, 3183-3192.	0.6	133
104	iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	133
105	In vivo imaging of graft-versus-host-disease in mice. <i>Blood</i> , 2004, 103, 3590-3598.	0.6	132
106	IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. <i>Blood</i> , 2009, 114, 5375-5384.	0.6	132
107	Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5460-5465.	3.3	131
108	ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. <i>Science Translational Medicine</i> , 2015, 7, 308ra160.	5.8	131

#	ARTICLE	IF	CITATIONS
109	Keratinocyte Growth Factor Administered Before Conditioning Ameliorates Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation in Mice. <i>Blood</i> , 1998, 92, 3960-3967.	0.6	130
110	Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting. <i>Journal of Clinical Oncology</i> , 2006, 24, 5186-5193.	0.8	130
111	Recent advances in graft-versus-host disease (GVHD) prevention. <i>Immunological Reviews</i> , 1997, 157, 79-109.	2.8	129
112	Regulation of acute graft-versus-host disease by microRNA-155. <i>Blood</i> , 2012, 119, 4786-4797.	0.6	128
113	Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. <i>Blood</i> , 2002, 99, 4601-4609.	0.6	126
114	Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells. <i>Journal of Experimental Medicine</i> , 2007, 204, 129-139.	4.2	126
115	Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. <i>JCI Insight</i> , 2016, 1, e89278.	2.3	126
116	Chronic stimulation drives human NK cell dysfunction and epigenetic reprogramming. <i>Journal of Clinical Investigation</i> , 2019, 129, 3770-3785.	3.9	125
117	Differential Roles for CCR5 Expression on Donor T Cells during Graft-versus-Host Disease Based on Pretransplant Conditioning. <i>Journal of Immunology</i> , 2004, 173, 845-854.	0.4	124
118	Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. <i>Journal of Experimental Medicine</i> , 2014, 211, 2373-2383.	4.2	124
119	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021, 138, 2278-2289.	0.6	124
120	Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. <i>Blood</i> , 2009, 114, 5062-5070.	0.6	123
121	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. <i>JCI Insight</i> , 2018, 3, .	2.3	123
122	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- $\beta$ 2 production. <i>Blood</i> , 2017, 129, 2570-2580.	0.6	122
123	Eomesodermin promotes the development of type 1 regulatory T (T <sub>R</sub> 1) cells. <i>Science Immunology</i> , 2017, 2, .	5.6	118
124	Retinoic Acid and Rapamycin Differentially Affect and Synergistically Promote the Ex Vivo Expansion of Natural Human T Regulatory Cells. <i>PLoS ONE</i> , 2011, 6, e15868.	1.1	118
125	The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo. <i>Journal of Immunology</i> , 2011, 187, 1113-1119.	0.4	115
126	Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses through the PD-1/PD-L1 Axis. <i>Cancer Research</i> , 2014, 74, 3441-3453.	0.4	115



#	ARTICLE	IF	CITATIONS
127	GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. <i>Cancer Research</i> , 2017, 77, 5664-5675.	0.4	114
128	Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). <i>Blood</i> , 2005, 105, 3372-3380.	0.6	113
129	Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. <i>Blood</i> , 2018, 131, 2651-2660.	0.6	113
130	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021, 39, 1865-1877.	0.8	111
131	Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. <i>Blood</i> , 2005, 106, 3293-3299.	0.6	110
132	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. <i>Blood</i> , 2013, 122, 1510-1517.	0.6	104
133	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. <i>Blood</i> , 2015, 126, 1621-1628.	0.6	104
134	Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. <i>British Journal of Haematology</i> , 2016, 175, 191-207.	1.2	103
135	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	0.6	101
136	Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. <i>Blood</i> , 2003, 101, 3741-3748.	0.6	100
137	Engraftment of Severe Combined Immune Deficient Mice Receiving Allogeneic Bone Marrow Via In Utero or Postnatal Transfer. <i>Blood</i> , 1998, 92, 3949-3959.	0.6	98
138	ARID5B regulates metabolic programming in human adaptive NK cells. <i>Journal of Experimental Medicine</i> , 2018, 215, 2379-2395.	4.2	98
139	A New Murine Model for Bronchiolitis Obliterans Post-Bone Marrow Transplant. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 713-723.	2.5	97
140	Clinical perspectives for regulatory T cells in transplantation tolerance. <i>Seminars in Immunology</i> , 2011, 23, 462-468.	2.7	95
141	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. <i>Blood</i> , 2016, 128, 1013-1017.	0.6	95
142	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. <i>Immunity</i> , 2018, 48, 91-106.e6.	6.6	95
143	Fanconi Anemia Gene Editing by the CRISPR/Cas9 System. <i>Human Gene Therapy</i> , 2015, 26, 114-126.	1.4	94
144	Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. <i>Blood</i> , 2018, 131, 1858-1869.	0.6	94

#	ARTICLE	IF	CITATIONS
145	Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. <i>Blood</i> , 2001, 98, 467-474.	0.6	93
146	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 2489-2497.	0.6	92
147	Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. <i>Nature Communications</i> , 2020, 11, 1659.	5.8	92
148	Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. <i>Blood</i> , 2000, 96, 4350-4356.	0.6	91
149	Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. <i>Blood</i> , 2016, 128, 427-439.	0.6	91
150	Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. <i>Blood</i> , 2002, 100, 3400-3407.	0.6	90
151	Alternative donor hematopoietic cell transplantation for Fanconi anemia. <i>Blood</i> , 2015, 125, 3798-3804.	0.6	90
152	Minimal PD-1 expression in mouse and human NK cells under diverse conditions. <i>Journal of Clinical Investigation</i> , 2020, 130, 3051-3068.	3.9	90
153	Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. <i>Science Translational Medicine</i> , 2015, 7, 280rv2.	5.8	88
154	B Cells in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 16-23.	2.0	86
155	INTERLEUKIN-10 DOSE-DEPENDENT REGULATION OF CD4+ AND CD8+ T CELL-MEDIATED GRAFT-VERSUS-HOST DISEASE1. <i>Transplantation</i> , 1998, 66, 1220-1229.	0.5	86
156	Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. <i>JCI Insight</i> , 2019, 4, .	2.3	86
157	161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. <i>Blood Advances</i> , 2018, 2, 1459-1469.	2.5	85
158	STAT3 Signaling in CD4+ T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model. <i>Journal of Immunology</i> , 2010, 184, 764-774.	0.4	84
159	Systemic Delivery of <i>Salmonella typhimurium</i> Transformed with IDO shRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth. <i>Cancer Research</i> , 2012, 72, 6447-6456.	0.4	84
160	Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 1813-1825.	3.9	84
161	ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2021, 39, 1888-1898.	0.8	83
162	Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). <i>Blood</i> , 2011, 117, 839-847.	0.6	82

#	ARTICLE	IF	CITATIONS
163	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. <i>Journal of Clinical Investigation</i> , 2016, 126, 2642-2660.	3.9	81
164	Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 475-492.	12.5	80
165	Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. <i>Cell Stem Cell</i> , 2021, 28, 2062-2075.e5.	5.2	80
166	Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. <i>Blood</i> , 2012, 119, 619-628.	0.6	79
167	Current Concepts and Advances in Graft-Versus-Host Disease Immunology. <i>Annual Review of Immunology</i> , 2021, 39, 19-49.	9.5	79
168	CD30/CD30 Ligand (CD153) Interaction Regulates CD4+ T Cell-Mediated Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2004, 173, 2933-2941.	0.4	77
169	Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. <i>Blood Advances</i> , 2018, 2, 909-922.	2.5	76
170	Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. <i>Blood</i> , 2008, 111, 5242-5251.	0.6	75
171	TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. <i>Blood</i> , 2008, 112, 3508-3516.	0.6	75
172	Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. <i>Cancer Immunology Research</i> , 2018, 6, 766-775.	1.6	75
173	PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. <i>Blood</i> , 2011, 117, 1030-1041.	0.6	74
174	Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. <i>Blood</i> , 2012, 120, 2229-2239.	0.6	74
175	CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. <i>Npj Regenerative Medicine</i> , 2016, 1, .	2.5	74
176	How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. <i>Blood Advances</i> , 2018, 2, 2012-2019.	2.5	74
177	The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation. <i>Nature Communications</i> , 2019, 10, 354.	5.8	74
178	Cytokine mediators of chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 2452-2463.	3.9	74
179	Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. <i>Blood</i> , 2004, 103, 1158-1165.	0.6	73
180	Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation. <i>Blood</i> , 2015, 125, 2435-2444.	0.6	73

#	ARTICLE	IF	CITATIONS
181	Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. <i>British Journal of Haematology</i> , 1997, 96, 749-756.	1.2	72
182	Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). <i>Blood</i> , 2007, 110, 3480-3488.	0.6	72
183	Treatment of chronic graft-versus-host disease with bortezomib. <i>Blood</i> , 2014, 124, 1677-1688.	0.6	72
184	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	0.6	72
185	Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. <i>Journal of Clinical Investigation</i> , 2017, 127, 1574-1588.	3.9	72
186	Host T Cells Resist Graft-Versus-Host Disease Mediated by Donor Leukocyte Infusions. <i>Journal of Immunology</i> , 2000, 165, 4901-4909.	0.4	71
187	Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine Administration: Implications for Clinical Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1252-1257.	2.0	71
188	Patient-Specific Naturally Gene-Reverted Induced Pluripotent Stem Cells in Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1246-1254.	0.3	70
189	miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. <i>Blood</i> , 2016, 128, 1424-1435.	0.6	70
190	CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration. <i>Science Immunology</i> , 2019, 4, .	5.6	70
191	Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	70
192	PKC $\delta$ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 3774-3786.	3.9	70
193	Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs. <i>Journal of Investigative Dermatology</i> , 2020, 140, 338-347.e5.	0.3	69
194	PKC- $\delta$ function at the immunological synapse: prospects for therapeutic targeting. <i>Trends in Immunology</i> , 2011, 32, 358-363.	2.9	68
195	Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?. <i>Blood</i> , 2016, 127, 3117-3126.	0.6	68
196	Blockade of LIGHT/LT $\beta$ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2002, 109, 549-557.	3.9	68
197	GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28 $^{\text{hi}}$ CD8 $^+$ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression. <i>Blood</i> , 2010, 116, 5403-5418.	0.6	67
198	Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. <i>Journal of Immunology</i> , 2018, 200, 3926-3933.	0.4	67

#	ARTICLE	IF	CITATIONS
199	Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1017-1021.	2.0	65
200	Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. <i>Science Translational Medicine</i> , 2015, 7, 315ra191.	5.8	64
201	Increasing Regulatory T Cells With Interleukin-2 and Interleukin-2 Antibody Complexes Attenuates Lung Inflammation and Heart Failure Progression. <i>Hypertension</i> , 2016, 68, 114-122.	1.3	64
202	Therapeutic activity of multiple common $\hat{1}^3$ -chain cytokine inhibition in acute and chronic GVHD. <i>Blood</i> , 2015, 125, 570-580.	0.6	63
203	Acute graft-versus-host disease is regulated by an IL-17 $\hat{a}$ “sensitive microbiome. <i>Blood</i> , 2017, 129, 2172-2185.	0.6	63
204	Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. <i>Blood</i> , 2017, 129, 3121-3125.	0.6	63
205	The Role of B7 Costimulation by Murine Acute Myeloid Leukemia in the Generation and Function of a CD8+ T-Cell Line With Potent In Vivo Graft-Versus-Leukemia Properties. <i>Blood</i> , 1997, 89, 3477-3485.	0.6	62
206	<scp>TRAF</scp> 6 directs <scp>FOXP</scp> 3 localization and facilitates regulatory T $\hat{a}$ cell function through K63 $\hat{a}$ linked ubiquitination. <i>EMBO Journal</i> , 2019, 38, .	3.5	62
207	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	0.6	62
208	An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. <i>Experimental Hematology</i> , 2004, 32, 318-324.	0.2	60
209	Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. <i>Blood</i> , 2020, 136, 1442-1455.	0.6	60
210	A phase II trial of human recombinant Interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study. <i>Cancer</i> , 1995, 75, 2959-2965.	2.0	59
211	Ex vivo fucosylation of third-party human regulatory T cells enhances anti $\hat{a}$ “graft-versus-host disease potency in vivo. <i>Blood</i> , 2015, 125, 1502-1506.	0.6	59
212	Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9334-9344.	2.9	59
213	Combined OX40L and mTOR blockade controls effector T cell activation while preserving T <sub>reg</sub> reconstitution after transplant. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	59
214	Adaptive NK cell reconstitution is associated with better clinical outcomes. <i>JCI Insight</i> , 2019, 4, .	2.3	59
215	CD154 on the surface of CD4+CD25+ regulatory t cells contributes to skin transplant tolerance. <i>Transplantation</i> , 2003, 76, 1375-1379.	0.5	58
216	CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease. <i>Blood</i> , 2013, 122, 825-836.	0.6	58

#	ARTICLE	IF	CITATIONS
217	Cutting Edge: TGF- $\hat{1}$ <sup>2</sup> and Phosphatidylinositol 3-Kinase Signals Modulate Distinct Metabolism of Regulatory T Cell Subsets. <i>Journal of Immunology</i> , 2018, 201, 2215-2219.	0.4	58
218	A trispesific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. <i>Leukemia</i> , 2021, 35, 1586-1596.	3.3	57
219	Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005, 360, 1747-1767.	1.8	56
220	FoxP3 and Ezh2 regulate Tfr cell suppressive function and transcriptional program. <i>Journal of Experimental Medicine</i> , 2019, 216, 605-620.	4.2	56
221	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. <i>Blood</i> , 2015, 125, 3335-3346.	0.6	55
222	Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. <i>Nature Communications</i> , 2016, 7, 12021.	5.8	54
223	Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF- $\hat{1}$ $\pm$ -Dependent Intensification of Oxidative Stress and Tumor Cell Death. <i>Cell Metabolism</i> , 2018, 28, 228-242.e6.	7.2	54
224	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017, 2, .	2.3	53
225	Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells. <i>Blood</i> , 2010, 115, 4914-4922.	0.6	52
226	B-cell targeting in chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 1399-1405.	0.6	52
227	Notch Signaling at Later Stages of NK Cell Development Enhances KIR Expression and Functional Maturation. <i>Journal of Immunology</i> , 2014, 193, 3344-3354.	0.4	51
228	MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. <i>Blood</i> , 2018, 131, 1974-1986.	0.6	51
229	Ribosome-Targeting Antibiotics Impair T Cell Effector Function and Ameliorate Autoimmunity by Blocking Mitochondrial Protein Synthesis. <i>Immunity</i> , 2021, 54, 68-83.e6.	6.6	51
230	Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. <i>Blood</i> , 2016, 128, 794-804.	0.6	49
231	Maintenance of CD4 T cell fitness through regulation of Foxo1. <i>Nature Immunology</i> , 2018, 19, 838-848.	7.0	49
232	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. <i>Blood</i> , 2019, 134, 1670-1682.	0.6	49
233	Attenuation of Acute Graft-versus-Host Disease in the Absence of the Transcription Factor ROR $\hat{1}$ <sup>3t</sup> . <i>Journal of Immunology</i> , 2012, 189, 1765-1772.	0.4	48
234	A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1737-1743.	2.0	48

#	ARTICLE	IF	CITATIONS
235	Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. <i>Blood</i> , 2012, 120, 682-690.	0.6	47
236	Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. <i>Blood</i> , 2013, 122, 2125-2134.	0.6	47
237	Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. <i>Onc Immunology</i> , 2016, 5, e1075114.	2.1	47
238	Altered T-cell receptor $\alpha$ + $\beta$ CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor- $\beta$ -treated alloreactive T cells that do not induce graft-versus-host disease. <i>Blood</i> , 2001, 97, 565-571.	0.6	46
239	Peyer patches are not required for acute graft-versus-host disease after myeloablative conditioning and murine allogeneic bone marrow transplantation. <i>Blood</i> , 2006, 107, 410-412.	0.6	46
240	Cutting Edge: Identification of Autoreactive CD4+ and CD8+ T Cell Subsets Resistant to PD-1 Pathway Blockade. <i>Journal of Immunology</i> , 2015, 194, 3551-3555.	0.4	46
241	Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells. <i>Blood</i> , 2016, 128, 2568-2579.	0.6	46
242	Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 57.	2.2	46
243	Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. <i>JCI Insight</i> , 2019, 4, .	2.3	46
244	Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	46
245	Tolerance induction by third-party $\alpha$ cooff-the-shelf $\beta$ CD4+CD25+ Treg cells. <i>Experimental Hematology</i> , 2006, 34, 66-71.	0.2	45
246	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 668-675.	2.0	45
247	A critical role for donor-derived IL-22 in cutaneous chronic GVHD. <i>American Journal of Transplantation</i> , 2018, 18, 810-820.	2.6	45
248	Induction of immunosuppressive functions and NF- $\kappa$ B by FLIP in monocytes. <i>Nature Communications</i> , 2018, 9, 5193.	5.8	45
249	Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. <i>Blood</i> , 2011, 117, 7032-7041.	0.6	44
250	Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells. <i>Blood</i> , 2016, 127, 1930-1939.	0.6	44
251	ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings. <i>Science Signaling</i> , 2016, 9, ra73.	1.6	44
252	Advances in targeting co $\alpha$ inhibitory and co $\alpha$ stimulatory pathways in transplantation settings: the Yin to the Yang of $\beta$ cancer immunotherapy. <i>Immunological Reviews</i> , 2017, 276, 192-212.	2.8	44

#	ARTICLE	IF	CITATIONS
253	Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2377-2392.	3.0	44
254	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019, 3, 2550-2561.	2.5	44
255	Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: Effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 277-284.	2.0	43
256	Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. <i>JCI Insight</i> , 2016, 1, e86850.	2.3	43
257	Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. <i>Journal of Immunology</i> , 2017, 198, 2500-2512.	0.4	43
258	Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy. , 2017, 5, 33.		43
259	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. <i>Frontiers in Immunology</i> , 2017, 8, 1844.	2.2	43
260	Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. <i>Cancer Gene Therapy</i> , 2020, 27, 235-245.	2.2	42
261	CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates. <i>Journal of Clinical Investigation</i> , 2018, 128, 3991-4007.	3.9	42
262	The Balance Between Donor T Cell Anergy and Suppression Versus Lethal Graft-Versus-Host Disease Is Determined by Host Conditioning. <i>Journal of Immunology</i> , 2002, 169, 5581-5589.	0.4	41
263	Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 962-969.	2.0	41
264	Stromal cell-derived factor-1 and hematopoietic cell homing in an adult zebrafish model of hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 766-774.	0.6	41
265	Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. <i>Cytotherapy</i> , 2017, 19, 250-262.	0.3	41
266	Persistent STAT5 activation reprograms the epigenetic landscape in CD4 <sup>+</sup> T cells to drive polyfunctionality and antitumor immunity. <i>Science Immunology</i> , 2020, 5, .	5.6	40
267	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. <i>Blood Advances</i> , 2021, 5, 1425-1436.	2.5	39
268	Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8 <sup>+</sup> T cells drive gastrointestinal acute graft-versus-host disease. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	39
269	Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4 <sup>+</sup> IL17 <sup>+</sup> response. , 2014, 2, 4.		38
270	Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation. <i>European Journal of Immunology</i> , 2015, 45, 2335-2342.	1.6	38



#	ARTICLE	IF	CITATIONS
271	Increased Effector Memory Insulin-Specific CD4+ T Cells Correlate With Insulin Autoantibodies in Patients With Recent-Onset Type 1 Diabetes. <i>Diabetes</i> , 2017, 66, 3051-3060.	0.3	38
272	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. <i>Blood</i> , 2017, 130, 2131-2145.	0.6	37
273	miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg). <i>Cell Death and Disease</i> , 2018, 9, 290.	2.7	37
274	Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. <i>Molecular Therapy</i> , 2018, 26, 1423-1434.	3.7	37
275	Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. <i>JCI Insight</i> , 2016, 1, .	2.3	37
276	Chemokine treatment rescues profound T-lineage progenitor homing defect after bone marrow transplant conditioning in mice. <i>Blood</i> , 2014, 124, 296-304.	0.6	36
277	Isoform-specific targeting of ROCK proteins in immune cells. <i>Small GTPases</i> , 2016, 7, 173-177.	0.7	36
278	Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. <i>JCI Insight</i> , 2020, 5, .	2.3	35
279	Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia. <i>Journal of Clinical Investigation</i> , 2020, 130, 1315-1329.	3.9	35
280	Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 $\beta$ (CCL3) after allogeneic BMT in mice. <i>Blood</i> , 2003, 101, 3714-3721.	0.6	34
281	Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T <sub>H</sub> 1 cell immunity. <i>Immunity</i> , 2021, 54, 2354-2371.e8.	6.6	34
282	Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethality. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 197-207.	2.0	33
283	Pig Embryonic Pancreatic Tissue as a Source for Transplantation in Diabetes. <i>Diabetes</i> , 2009, 58, 1585-1594.	0.3	33
284	Keratinocytes from Induced Pluripotent Stem Cells in Junctional Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2013, 133, 562-565.	0.3	33
285	Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation. <i>Journal of Leukocyte Biology</i> , 2017, 102, 335-341.	1.5	32
286	GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity. <i>Blood</i> , 2017, 129, 630-642.	0.6	32
287	Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2297-2302.	2.0	32
288	Blockade of LIGHT/LT $\beta$ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2002, 109, 549-557.	3.9	32

#	ARTICLE	IF	CITATIONS
289	The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 4604-4621.	3.9	32
290	Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease. <i>Trends in Immunology</i> , 2020, 41, 77-91.	2.9	31
291	Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice. <i>Blood</i> , 2018, 132, 2188-2200.	0.6	30
292	Licensing delineates helper and effector NK cell subsets during viral infection. <i>JCI Insight</i> , 2017, 2, .	2.3	30
293	Obesity induces gut microbiota alterations and augments acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	29
294	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	0.6	29
295	Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and rapamycin. <i>Experimental Hematology</i> , 2006, 34, 802-808.	0.2	28
296	Prevention of Graft-versus-Host Disease by Adoptive T Regulatory Therapy Is Associated with Active Repression of Peripheral Blood Toll-Like Receptor 5 mRNA Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 173-182.	2.0	28
297	CD8-predominant T-cell CNS infiltration accompanies GVHD in primates and is improved with immunoprophylaxis. <i>Blood</i> , 2014, 123, 1967-1969.	0.6	28
298	The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. <i>Current Topics in Microbiology and Immunology</i> , 2015, 395, 225-243.	0.7	28
299	Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease. <i>Frontiers in Immunology</i> , 2019, 10, 309.	2.2	28
300	IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer. <i>Blood Advances</i> , 2020, 4, 1594-1605.	2.5	28
301	Follicular T cells mediate donor-specific antibody and rejection after solid organ transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 1893-1901.	2.6	28
302	Regulatory T cells. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 46-49.	2.0	27
303	Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2025-2030.	2.0	27
304	In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. <i>American Journal of Transplantation</i> , 2017, 17, 3098-3113.	2.6	27
305	A robust in vitro model for trans-lymphatic endothelial migration. <i>Scientific Reports</i> , 2017, 7, 1633.	1.6	27
306	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	2.5	27

#	ARTICLE	IF	CITATIONS
307	Regulatory T Cells Condition Lymphatic Endothelia for Enhanced Transendothelial Migration. <i>Cell Reports</i> , 2020, 30, 1052-1062.e5.	2.9	27
308	Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 4652-4662.	3.9	27
309	Effect of Sepsis Syndrome on Neonatal Protein and Energy Metabolism. <i>Journal of Perinatology</i> , 2000, 20, 96-100.	0.9	26
310	Bystander Activation and Anti-Tumor Effects of CD8+ T Cells Following Interleukin-2 Based Immunotherapy Is Independent of CD4+ T Cell Help. <i>PLoS ONE</i> , 2014, 9, e102709.	1.1	26
311	Differential Regulation of T-cell Immunity and Tolerance by Stromal Laminin Expressed in the Lymph Node. <i>Transplantation</i> , 2019, 103, 2075-2089.	0.5	26
312	ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. <i>Clinical Immunology</i> , 2021, 230, 108823.	1.4	26
313	Analysis of the Requirements for the Induction of CD4+ T Cell Alloantigen Hyporesponsiveness by Ex Vivo Anti-CD40 Ligand Antibody. <i>Journal of Immunology</i> , 2000, 164, 612-622.	0.4	25
314	T-cell expression of AhR inhibits the maintenance of pTreg cells in the gastrointestinal tract in acute GVHD. <i>Blood</i> , 2017, 130, 348-359.	0.6	25
315	IDO in Human Gut Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 150-155.	2.0	24
316	Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1899-1904.	2.0	24
317	CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. <i>Stem Cells and Development</i> , 2016, 25, 1591-1603.	1.1	24
318	MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. <i>Journal of Immunology</i> , 2018, 200, 4170-4179.	0.4	24
319	VISTA Re-programs Macrophage Biology Through the Combined Regulation of Tolerance and Anti-inflammatory Pathways. <i>Frontiers in Immunology</i> , 2020, 11, 580187.	2.2	24
320	CRISPR/Cas9-Based Lateral Flow and Fluorescence Diagnostics. <i>Bioengineering</i> , 2021, 8, 23.	1.6	24
321	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	0.6	24
322	C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans. <i>JCI Insight</i> , 2018, 3, .	2.3	24
323	Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 879-883.	2.0	23
324	Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T <sup>H</sup> cells and hematopoietic stem and progenitor cells using base editing. <i>Molecular Therapy</i> , 2022, 30, 130-144.	3.7	23

#	ARTICLE	IF	CITATIONS
325	Unrelated Donor Bone Marrow Transplantation for Hematological Malignancies-Current Status. <i>Leukemia and Lymphoma</i> , 1996, 23, 221-226.	0.6	22
326	Programming of donor T cells using allogeneic $\hat{\imath}$ -like ligand 4 $\hat{\imath}$ positive dendritic cells to reduce GVHD in mice. <i>Blood</i> , 2016, 127, 3270-3280.	0.6	22
327	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. <i>JHEP Reports</i> , 2022, 4, 100386.	2.6	22
328	Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling. <i>Cancer Research</i> , 2016, 76, 6802-6815.	0.4	21
329	B Cells Drive Autoimmunity in Mice with CD28-Deficient Regulatory T Cells. <i>Journal of Immunology</i> , 2017, 199, 3972-3980.	0.4	21
330	Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. <i>Blood</i> , 2018, 131, 1743-1754.	0.6	21
331	Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets. <i>PLoS ONE</i> , 2019, 14, e0217761.	1.1	21
332	Reduction in murine acute GVHD severity by human gingival tissue-derived mesenchymal stem cells via the CD39 pathways. <i>Cell Death and Disease</i> , 2019, 10, 13.	2.7	21
333	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019, 133, 94-99.	0.6	21
334	IFN- $\hat{\imath}$ therapy prevents severe gastrointestinal graft-versus-host disease. <i>Blood</i> , 2021, 138, 722-737.	0.6	21
335	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641.	0.6	21
336	The lymph node stromal laminin $\hat{\imath}\pm 5$ shapes alloimmunity. <i>Journal of Clinical Investigation</i> , 2020, 130, 2602-2619.	3.9	21
337	Osteosarcoma Derived from Cultured Mesenchymal Stem Cells.. <i>Blood</i> , 2006, 108, 2554-2554.	0.6	21
338	Understanding Chronic GVHD from Different Angles. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S184-S188.	2.0	20
339	Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. <i>Haematologica</i> , 2016, 101, 764-772.	1.7	20
340	Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant. , 2016, 4, 11.		20
341	IL-7 signaling imparts polyfunctionality and stemness potential to CD4 <sup>+</sup> T cells. <i>Oncolmmunology</i> , 2016, 5, e1171445.	2.1	20
342	Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2018, 378, 585-586.	13.9	20

#	ARTICLE	IF	CITATIONS
343	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. <i>Blood Advances</i> , 2021, 5, 1069-1080.	2.5	20
344	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2887.	2.2	19
345	CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 946.	1.8	19
346	Effective Multi-lineage Engraftment in a Mouse Model of Fanconi Anemia Using Non-genotoxic Antibody-Based Conditioning. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 455-464.	1.8	19
347	A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice. <i>Blood</i> , 2022, 139, 1743-1759.	0.6	19
348	Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 804-811.	2.0	18
349	Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol. <i>Cytotherapy</i> , 2019, 21, 1216-1233.	0.3	18
350	Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease. <i>JCI Insight</i> , 2019, 4, .	2.3	18
351	Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease. <i>JCI Insight</i> , 2019, 4, .	2.3	18
352	T cell progenitor therapy“facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction. <i>JCI Insight</i> , 2017, 2, .	2.3	18
353	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. <i>Nature Communications</i> , 2022, 13, 2176.	5.8	18
354	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 2889-2899.	0.6	17
355	Pediatric acute GVHD: clinical phenotype and response to upfront steroids. <i>Bone Marrow Transplantation</i> , 2020, 55, 165-171.	1.3	17
356	GCNT1-Mediated <i>O</i> -Glycosylation of the Sialomucin CD43 Is a Sensitive Indicator of Notch Signaling in Activated T Cells. <i>Journal of Immunology</i> , 2020, 204, 1674-1688.	0.4	17
357	Intestinal Helminths Regulate Lethal Acute Graft-versus-Host Disease and Preserve the Graft-versus-Tumor Effect in Mice. <i>Journal of Immunology</i> , 2015, 194, 1011-1020.	0.4	16
358	Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	16
359	Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9676.	1.8	16
360	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.	1.7	15

#	ARTICLE	IF	CITATIONS
361	Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. <i>Blood Advances</i> , 2018, 2, 2307-2319.	2.5	15
362	ICOSL <sup>+</sup> plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	15
363	STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	15
364	Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions. <i>Journal of Pediatrics</i> , 2020, 223, 183-185.	0.9	15
365	Effect of Radiation Dose-Rate on Hematopoietic Cell Engraftment in Adult Zebrafish. <i>PLoS ONE</i> , 2013, 8, e73745.	1.1	14
366	Nfatc2 and Tob1 Have Non-Overlapping Function in T Cell Negative Regulation and Tumorigenesis. <i>PLoS ONE</i> , 2014, 9, e100629.	1.1	14
367	A Functional Bioluminescent Zebrafish Screen for Enhancing Hematopoietic Cell Homing. <i>Stem Cell Reports</i> , 2017, 8, 177-190.	2.3	14
368	Generation and function of progenitor T cells from StemRegenin-1 <sup>+</sup> expanded CD34 <sup>+</sup> human hematopoietic progenitor cells. <i>Blood Advances</i> , 2019, 3, 2934-2948.	2.5	14
369	Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. <i>Biomedicines</i> , 2020, 8, 617.	1.4	14
370	Validation of Minnesota acute graft-versus-host disease Risk Score. <i>Haematologica</i> , 2020, 105, 519-524.	1.7	14
371	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020, 135, 28-40.	0.6	14
372	Donor bone marrow <sup>+</sup> derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice. <i>Blood</i> , 2022, 139, 1389-1408.	0.6	14
373	<i>sdfl</i> Expression Reveals a Source of Perivascular-Derived Mesenchymal Stem Cells in Zebrafish. <i>Stem Cells</i> , 2014, 32, 2767-2779.	1.4	13
374	Preclinical Testing of Antihuman CD28 Fab <sup>+</sup> Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease. <i>Transplantation</i> , 2016, 100, 2630-2639.	0.5	13
375	Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. <i>Oncolmmunology</i> , 2016, 5, e1160184.	2.1	13
376	Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2020, 11, 181.	2.2	13
377	Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 618-622.	2.0	13
378	$\beta$ -Adrenergic receptor activation on donor cells ameliorates acute GvHD. <i>JCI Insight</i> , 2020, 5, .	2.3	13

#	ARTICLE	IF	CITATIONS
379	Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 281-289.	1.7	12
380	Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells. <i>Blood</i> , 2019, 134, 776-781.	0.6	12
381	Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity. <i>JCI Insight</i> , 2020, 5, .	2.3	12
382	Antibodies to CD40 Promote Dendritic Cell Recovery and Anti-Tumor Effects after Syngeneic Bone Marrow Transplant (BMT).. <i>Blood</i> , 2005, 106, 1305-1305.	0.6	12
383	FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1341-1352.	2.0	11
384	In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination. <i>Stem Cells</i> , 2015, 33, 3174-3180.	1.4	11
385	Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 825-833.	2.0	11
386	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. <i>Clinical Cancer Research</i> , 2021, 27, 2712-2722.	3.2	11
387	Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213). <i>Blood</i> , 2020, 136, 45-46.	0.6	11
388	Induction of transplantation tolerance by combining non-myeloablative conditioning with delivery of alloantigen by T cells. <i>Clinical Immunology</i> , 2008, 127, 130-137.	1.4	10
389	STAT6 and Furin Are Successive Triggers for the Production of TGF- $\beta$ 2 by T Cells. <i>Journal of Immunology</i> , 2018, 201, 2612-2623.	0.4	10
390	Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2190-2196.	2.0	10
391	Early Notch Signals Induce a Pathogenic Molecular Signature during Priming of Alloantigen-Specific Conventional CD4+ T Cells in Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2019, 203, 557-568.	0.4	10
392	Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality. <i>Journal of Immunology</i> , 2019, 202, 2795-2805.	0.4	10
393	Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid. <i>Modern Pathology</i> , 2019, 32, 560-567.	2.9	10
394	Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth. <i>Cancers</i> , 2021, 13, 3565.	1.7	10
395	Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. <i>Frontiers in Immunology</i> , 2021, 12, 757836.	2.2	10
396	Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for nonmalignant diseases. <i>Blood</i> , 2022, 139, 3583-3593.	0.6	10

#	ARTICLE	IF	CITATIONS
397	Cytolytic CD4+ and CD8+ Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2022, 13, 864748.	2.2	10
398	IL-33 acts as a costimulatory signal to generate alloreactive Th1 cells in graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	10
399	Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1541-1552.	2.0	9
400	Helminth-Induced Production of TGF- $\beta$ 2 and Suppression of Graft-versus-Host Disease Is Dependent on IL-4 Production by Host Cells. <i>Journal of Immunology</i> , 2018, 201, 2910-2922.	0.4	9
401	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 56-62.	2.0	9
402	Targeting PI3K $\beta$ function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	2.6	9
403	PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment. <i>Frontiers in Immunology</i> , 2020, 11, 590568.	2.2	9
404	Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. <i>Bone Marrow Transplantation</i> , 2021, 56, 1238-1247.	1.3	9
405	Inflammasome effects in GvHD. <i>Oncotarget</i> , 2015, 6, 38444-38445.	0.8	9
406	Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD. <i>Blood Advances</i> , 2021, 5, 4578-4589.	2.5	9
407	Mechanisms by Which Obesity Promotes Acute Graft-Versus-Host Disease in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 752484.	2.2	9
408	Understanding Luminal Microorganisms and Their Potential Effectiveness in Treating Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 194-201.	0.9	8
409	A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression. <i>PLoS ONE</i> , 2018, 13, e0193461.	1.1	8
410	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. <i>Blood</i> , 2021, 137, 1090-1103.	0.6	8
411	Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects. <i>Blood</i> , 2021, 138, 2583-2588.	0.6	8
412	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. <i>JCI Insight</i> , 2019, 4, .	2.3	8
413	Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment. <i>Blood</i> , 2020, 136, 1-2.	0.6	8
414	Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. <i>Cell Death and Disease</i> , 2021, 12, 1005.	2.7	8



#	ARTICLE	IF	CITATIONS
415	Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial.. Blood, 2004, 104, 1825-1825.	0.6	8
416	Retinoic acid signaling acts as a rheostat to balance Treg function. , 2022, 19, 820-833.		8
417	Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. Cytotherapy, 2021, 23, 704-714.	0.3	7
418	Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control. Frontiers in Cell and Developmental Biology, 2021, 9, 737880.	1.8	7
419	Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant. Bone Marrow Transplantation, 2021, 56, 1373-1380.	1.3	7
420	KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208). Blood, 2019, 134, 872-872.	0.6	7
421	Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT. JCI Insight, 2021, 6, .	2.3	7
422	Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant. Blood Advances, 2020, 4, 4232-4243.	2.5	6
423	KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) â€” Pharmacodynamics and Updated Results. Blood, 2018, 132, 602-602.	0.6	6
424	Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation. Blood, 2010, 116, 225-225.	0.6	6
425	BET-bromodomain and EZH2 inhibitorâ€”treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood, 2022, 139, 2983-2997.	0.6	6
426	Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTNâ€”0201 and â€”0901 samples. British Journal of Haematology, 2018, 182, 887-894.	1.2	5
427	Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells. JCI Insight, 2021, 6, .	2.3	5
428	P63 targeted deletion under the FOXN1 promoter disrupts pre-and post-natal thymus development, function and maintenance as well as induces severe hair loss. PLoS ONE, 2022, 17, e0261770.	1.1	5
429	Reprint of: B Cells in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, S11-S18.	2.0	4
430	Regulatory T cell expressed MyD88 is critical for prolongation of allograft survival. Transplant International, 2016, 29, 930-940.	0.8	4
431	Thymic Epithelial Cell Support of Thymopoiesis Does Not Require Klotho. Journal of Immunology, 2018, 201, 3320-3328.	0.4	4
432	Early E. casseliflavus gut colonization and outcomes of allogeneic hematopoietic cell transplantation. PLoS ONE, 2019, 14, e0220850.	1.1	4

#	ARTICLE	IF	CITATIONS
433	An alpha-defensin gene single nucleotide polymorphism modulates the gut microbiota and may alter the risk of acute graft-versus-host disease. <i>British Journal of Haematology</i> , 2020, 189, 926-930.	1.2	4
434	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. <i>Blood Cancer Journal</i> , 2021, 11, 96.	2.8	4
435	NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death. <i>Blood</i> , 2019, 134, 3215-3215.	0.6	4
436	Host Indoleamine 2,3-Dioxygenase Is a Critical Regulator of Acute GVHD Lethality.. <i>Blood</i> , 2007, 110, 352-352.	0.6	4
437	Immune Reconstitution after Umbilical Cord Blood Versus Peripheral Blood Progenitor Cell Transplantation in Adults Following Myeloablative Conditioning. <i>Blood</i> , 2016, 128, 2246-2246.	0.6	4
438	Ex Vivo Blockade of NF- $\kappa$ B Signaling in Alloreactive T Cells Prevents Murine Graft-Versus-Host Disease (GVHD).. <i>Blood</i> , 2004, 104, 3058-3058.	0.6	4
439	Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal. <i>Blood</i> , 2018, 132, 67-67.	0.6	4
440	Analyses and Correlation of Pathologic and Ocular Cutaneous Changes in Murine Graft versus Host Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 184.	1.8	4
441	Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 700.e1-700.e6.	0.6	4
442	Strategies to Inhibit Alloantibody Production in Alloprimed Murine Recipients of Hematopoietic Stem Cell Grafts. <i>American Journal of Transplantation</i> , 2015, 15, 931-941.	2.6	3
443	Cadherin 17 mutation associated with leaky severe combined immune deficiency is corrected by HSCT. <i>Blood Advances</i> , 2017, 1, 2083-2087.	2.5	3
444	Despite high levels of expression in thymic epithelial cells, miR-181a1 and miR-181b1 are not required for thymic development. <i>PLoS ONE</i> , 2018, 13, e0198871.	1.1	3
445	Shotgun sequencing of the faecal microbiome to predict response to steroids in patients with lower gastrointestinal acute graft-versus-host disease: An exploratory analysis. <i>British Journal of Haematology</i> , 2021, 192, e69-e73.	1.2	3
446	Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD). <i>Blood</i> , 2019, 134, 804-804.	0.6	3
447	Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair. <i>American Journal of Transplantation</i> , 2021, , .	2.6	3
448	Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802. <i>Blood</i> , 2017, 130, 72-72.	0.6	3
449	Divergent fates of antigen-specific CD8+ T $\alpha$ cell clones in mice with acute leukemia. <i>Cell Reports</i> , 2021, 37, 109991.	2.9	3
450	Predictors and outcomes of flares in chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	3

#	ARTICLE	IF	CITATIONS
451	The E. Donnell Thomas Lecture. Biology of Blood and Marrow Transplantation, 2005, 11, 651-656.	2.0	2
452	Immune Regulatory Cell Biology and Clinical Applications to Prevent or Treat Acute Graft-Versus-Host Disease. Engineering, 2019, 5, 98-105.	3.2	2
453	An irradiated marrow niche reveals a small non-collagenous protein mediator of homing, dermatopontin. Blood Advances, 2021, 5, 3609-3622.	2.5	2
454	Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. Cancer Immunology, Immunotherapy, 1994, 38, 135-141.	2.0	2
455	Pharmacologic Blockade of Notch/Delta-like Ligand 4 Signaling Protects from Gastrointestinal Acute Graft-Versus-Host Disease in Non-Human Primates. Blood, 2018, 132, 2027-2027.	0.6	2
456	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. Blood, 2018, 132, 71-71.	0.6	2
457	PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets. Blood, 2019, 134, 621-621.	0.6	2
458	Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease. Blood, 2020, 136, 14-14.	0.6	2
459	Toll-Like Receptor 7-Targeting of Human B-Lineage Acute Lymphocytic Leukemia Induces Immunogenicity and Apoptosis of Leukemia Cells.. Blood, 2006, 108, 706-706.	0.6	2
460	Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells and Suppresses Circulating T Follicular Helper Cells in Patients with Chronic Gvhd. Blood, 2017, 130, 74-74.	0.6	2
461	Corticosteroid Treatment Impairs Epithelial Regeneration, Limiting Intestinal Recovery in Experimental Graft Vs Host Disease. Blood, 2021, 138, 88-88.	0.6	2
462	Regulatory T cells: A review of manufacturing and clinical utility. Transfusion, 2022, 62, 904-915.	0.8	2
463	High cutaneous amphiregulin expression predicts fatal acute <scp>graftâ€versusâ€host</scp> disease. Journal of Cutaneous Pathology, 2022, , .	0.7	2
464	Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. Bone Marrow Transplantation, 2018, 53, 1069-1071.	1.3	1
465	Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. Bone Marrow Transplantation, 2019, 54, 490-493.	1.3	1
466	Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Advances, 2020, 4, 2317-2324.	2.5	1
467	Activation Status Dictates the Function of Unlicensed Natural Killer Cells. Blood Advances, 2021, 5, 4219-4232.	2.5	1
468	First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 2112-2112.	0.6	1

#	ARTICLE	IF	CITATIONS
469	Innate Lymphoid Cell-Derived IL-22 Regulates Epithelial Recovery From Gvhd. <i>Blood</i> , 2012, 120, 339-339.	0.6	1
470	MiR-155 Impacts T Cell Migration in Acute Graft-Versus-Host Disease (aGVHD). <i>Blood</i> , 2015, 126, 3080-3080.	0.6	1
471	Mucocutaneous Engraftment and Type VII Collagen (C7) Replacement after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). <i>Blood</i> , 2015, 126, 402-402.	0.6	1
472	Stable Gene Transfer and Expression in Human Primary T-Cells by the Sleeping Beauty Transposon System.. <i>Blood</i> , 2005, 106, 5539-5539.	0.6	1
473	Correction of the Skin Defect in Murine Recessive Dystrophic Epidermolysis Bullosa by Bone Marrow Derived SLAM Family Receptor Enriched Cells.. <i>Blood</i> , 2007, 110, 435-435.	0.6	1
474	Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).. <i>Blood</i> , 2007, 110, 2160.5-2160.5.	0.6	1
475	iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo. <i>Blood</i> , 2019, 134, 1933-1933.	0.6	1
476	Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia. <i>Blood</i> , 2019, 134, 196-196.	0.6	1
477	Belumosudil for Patients with Chronic Graft-Versus-Host Disease: Combined Analysis of Failure-Free Survival (FFS) in the KD025-208 and Pivotal Rockstar Trials. <i>Blood</i> , 2021, 138, 3898-3898.	0.6	1
478	Single Agent CD45-Targeted Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model. <i>Blood</i> , 2020, 136, 31-31.	0.6	1
479	Treg tissue stability depends on lymphotoxin beta-receptor- and adenosine-receptor-driven lymphatic endothelial cell responses. <i>Cell Reports</i> , 2022, 39, 110727.	2.9	1
480	Distinct Roles for Donor and Host Antigen Presenting Cells and Costimulatory Molecules in Murine Chronic Graft-Vs-Host Disease: Requirements Depend on Target Organ.. <i>Blood</i> , 2004, 104, 3059-3059.	0.6	0
481	Reduced Intensity Compared to High Dose Conditioning for Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Comparative Clinical Analysis.. <i>Blood</i> , 2004, 104, 1817-1817.	0.6	0
482	Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. <i>Blood</i> , 2004, 104, 2148-2148.	0.6	0
483	Real-Time In Vivo Biodistribution of Multipotent Adult Progenitor Cells (MAPC): Role of the Immune System in MAPC Resistance in Non-Transplanted and Bone Marrow Transplanted Mice.. <i>Blood</i> , 2004, 104, 507-507.	0.6	0
484	In Vitro System for Generation of Leukemia-Specific Cytotoxic T Cells for Adoptive Immunotherapy.. <i>Blood</i> , 2005, 106, 1065-1065.	0.6	0
485	Mesenchymal Cancer Cells Can Arise from Ex Vivo Modified Mesenchymal Stem Cells.. <i>Blood</i> , 2005, 106, 4326-4326.	0.6	0
486	The Unexpected and Differential Effect of Cyclosporin A on CD56Bright and CD56Dim NK Cell Expansion, Phenotype, Function and Development from Progenitor Cells.. <i>Blood</i> , 2005, 106, 1404-1404.	0.6	0

#	ARTICLE	IF	CITATIONS
487	Removal of Donor CD4+ T Cells Markedly Promotes Graft-Versus-Tumor (GVT) Effects and Inhibits GVHD-Dependent Toxicity Associated with Prolonged Bortezomib Administration after Allogeneic BMT.. Blood, 2006, 108, 3160-3160.	0.6	0
488	Induction of Endogenous Repair Mechanisms by Single-Stranded DNA Oligonucleotide Therapy for Correction of the DNA-PK Mutation in Murine Severe Combined Immune Deficiency.. Blood, 2006, 108, 454-454.	0.6	0
489	Sleeping Beauty (SB) Transposon Mediated Umbilical Cord Blood (UCB) T Cell Therapy for Refractory Acute Lymphoblastic Leukemia (ALL).. Blood, 2006, 108, 722-722.	0.6	0
490	In Vivo CpG Administration Accelerates Graft-Versus-Host Disease (GVHD) Lethality by Toll-Like Receptor 9 (TLR9) Ligation of Host Antigen-Presenting Cells (APCs) and Promotes Allogeneic Bone Marrow (BM) Rejection by TLR9 Ligation of Donor APCs.. Blood, 2006, 108, 446-446.	0.6	0
491	Dissociating GVT from GVHD in Murine BMT Models through TNF $\alpha$ Dependent CD4+ T Cell Mediated GVHD and IFN $\gamma$ Dependent CD8+ T Cell Mediated Anti-Tumor Effects.. Blood, 2007, 110, 69-69.	0.6	0
492	Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).. Blood, 2007, 110, 3951-3951.	0.6	0
493	Comparisons of the regulatory function of ex vivo expanded polyclonal or antigen-specific non-human primate T regulatory cells. FASEB Journal, 2008, 22, 862.16.	0.2	0
494	KGF and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T cell reconstitution following murine BMT. FASEB Journal, 2008, 22, 536-536.	0.2	0
495	Treg Depletion with Interleukin-2-Diphtheriatoxin (IL-2DT) Is Sufficient to Induce Tumor Clearance in Acute Myeloid Leukemia (AML). Blood, 2008, 112, 2954-2954.	0.6	0
496	Critical and Opposing Effects of T Cell-Derived TNF $\alpha$ and Interferon- $\gamma$ on IL-17 Induction Assessed in Vitro and in Vivo Following Allogeneic Bone Marrow Transplantation. Blood, 2008, 112, 3482-3482.	0.6	0
497	Tim-3, a Novel Immune Receptor, Is Constitutively Expressed on Human Natural Killer Cells and Functions as An Activating Coreceptor. Blood, 2010, 116, 106-106.	0.6	0
498	In Vitro Generation of NK22 Cells From Hematopoietic Stem Cells. Blood, 2010, 116, 108-108.	0.6	0
499	DNA Methylation Profile of Runx1 Regulatory Regions Is Correlated with Transition From Primitive to Definitive Hematopoietic Potential In Vitro and In Vivo. Blood, 2011, 118, 389-389.	0.6	0
500	Allogeneic Hematopoietic Cell Transplantation for Severe Epidermolysis Bullosa: Impact of Conditioning Regimen and Stem Cell Source On Outcomes. Blood, 2012, 120, 965-965.	0.6	0
501	A Randomized Trial of One Vs. Two Doses of Influenza Vaccine Following Allogeneic Transplantation. Blood, 2012, 120, 1896-1896.	0.6	0
502	Chronic GvHD Is Characterized By Impaired B Cell Development in the Bone Marrow. Blood, 2015, 126, 1883-1883.	0.6	0
503	Defining Successful Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2015, 126, 1934-1934.	0.6	0
504	Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells. Blood, 2016, 128, 808-808.	0.6	0

#	ARTICLE	IF	CITATIONS
505	Ex-Vivo Fucosylation Improves the Anti-Graft-Versus-Host-Disease Effects of Mesenchymal Stem Cells in the NOD/SCID/IL-2R Null Mouse Model. <i>Blood</i> , 2016, 128, 4559-4559.	0.6	0
506	Mechanism and Activity of ILC2 Cells Post Allo-BMT. <i>Blood</i> , 2016, 128, 1155-1155.	0.6	0
507	Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy. <i>Blood</i> , 2017, 130, 656-656.	0.6	0
508	A Critical Role for Donor-Derived IL-22 in Cutaneous Chronic Gvhd. <i>Blood</i> , 2017, 130, 69-69.	0.6	0
509	Uncovering the Molecular Signature of Pathogenic Tissue-Infiltrating T Cells during Acute Graft-Versus-Host Disease. <i>Blood</i> , 2018, 132, 805-805.	0.6	0
510	IL2 and Rapamycin Enhance Persistence of Adoptively-Transferred Ex-Vivo Expanded T Regulatory Cells. <i>Blood</i> , 2018, 132, 2049-2049.	0.6	0
511	ST2 and ROR- $\gamma$ t Roles in Intestinal Regulatory T Cells. <i>Blood</i> , 2018, 132, 66-66.	0.6	0
512	Intestinal Immune Conditioning with Helminths Employs Host T Helper 2 (Th2) Pathway to Induce Mixed Chimerism and Regulate Graft-Versus-Host Disease. <i>Blood</i> , 2018, 132, 2036-2036.	0.6	0
513	Donor T Cells Require Notch Signals but Not Alloantigen Presentation from Specialized Secondary Lymphoid Organ Fibroblasts to Drive Graft-Versus-Host Disease. <i>Blood</i> , 2018, 132, 810-810.	0.6	0
514	Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprogramming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept. <i>Blood</i> , 2019, 134, 596-596.	0.6	0
515	Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1922-1922.	0.6	0
516	Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD. <i>Blood</i> , 2019, 134, 3205-3205.	0.6	0
517	The Innate Immune Sensor Sting Promotes Donor CD8+ T Cell Activation and Recipient APC Death Early after Preclinical Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 3202-3202.	0.6	0
518	Dll1 and Dll4 Notch Ligands Prime T Cell Alloimmunity and Are Expressed in Non-Overlapping Populations of Fibroblastic Stromal Cells in Spleen and Lymph Nodes at the Onset of Gvhd. <i>Blood</i> , 2019, 134, 588-588.	0.6	0
519	Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT). <i>Blood</i> , 2019, 134, 2009-2009.	0.6	0
520	Galectin-3 Signaling in Donor T Cells Regulates Acute Graft Versus Host Disease (aGvHD) after Allogeneic Transplantation. <i>Blood</i> , 2021, 138, 2765-2765.	0.6	0
521	Prevention of Acute Graft-Versus-Host Disease Using an Engineered Mouse Orthogonal IL-2/IL-2R $\beta$ Regulatory T Cells. <i>Blood</i> , 2021, 138, 1688-1688.	0.6	0
522	Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML. <i>Blood</i> , 2020, 136, 57-58.	0.6	0

#	ARTICLE	IF	CITATIONS
523	High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease. Blood, 2020, 136, 44-46.	0.6	0
524	Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease. Blood, 2020, 136, 47-48.	0.6	0
525	Predicting Immune Pathology after Hematopoietic Stem Cell Transplant with Transcriptomics: Naïve CD4 T Cell Expansion at Day 100 Predicts Patients with De Novo Chronic Gvhd. Blood, 2020, 136, 38-39.	0.6	0
526	Tissue-Derived IL-33 Is a Critical Local Signal That Targets Th1 Cells in the Small Intestine to Sustain Graft Versus Host Disease in the Absence of IL-12. Blood, 2020, 136, 1-2.	0.6	0
527	Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease. Frontiers in Immunology, 2022, 13, 765319.	2.2	0